Treating COVID-19 with Anticoagulation Based on Kabir Bleeding Risk Score

Three large randomized clinical trials named the ATTACC, ACTIV-4a, and REMAP-CAP were terminated early as these trials showed use of therapeutic anticoagulation among non-critical COVID-19 patients increased the probability of survival to hospital discharge as well as reduced the need for cardiovascular or respiratory organ support. These clinical trials also showed when a COVID-19 patient presents with a critical stage, therapeutic anticoagulation does not provide any benefit. This study retrospectively evaluated the COVID-19 admission at Jackson Hospital, Alabama, USA from June 15th, 2020, to June 15th, 2021. The study developed COVID-19 mechanism of death and found that anticoagulation doses can be titrated up or down based on D-Dimer trends and many patients do not need therapeutic anticoagulation, rather an intermediate dose (Lovenox 0.5mg/kg subQ BID or higher dose) anticoagulation can be sufficient for those who have a higher risk of bleeding. The author developed the Kabir bleeding risk score-based treatment strategies for COVID-19 patients which can be visited by clicking on the following link: .